As reported by Reuters,1 the online weight loss company will have its own version of compounded semaglutide available via its marketplace. The ingredient is not only found in Wegovy but also Ozempic, another GLP-1 produced by the Danish manufacturer.
Following FDA protocol
Noom has been on the record as saying that it plans to fully abide by FDA regulations, but being that the semaglutide shortage is officially over2 and the final deadline for compounders to stop producing it is May 22, it remains to be seen how or if the FDA will take action. On its website, the teleleath site writes3 that “compounded semaglutide mimics GLP-1 (glucagon-like peptide-1), a naturally occurring hormone your body produces that helps you feel full and satisfied after you eat,” meaning that there is a distinction between the original semaglutide and its compounded version. However, it also technically belongs to the GLP-1 receptor agonist class, which is the where the confusion arises.
Meanwhile, Geoff Cook, Noom’s CEO, noted that selling this product would not interfere with any current regulations, commenting to Reuters that “there is a personalized, and there has always been a personalized, exception.”
Especially as of late, the sale of weight loss drugs by telehealth companies has been a trend. As the public may recall, Hims & Hers began selling various Eli Lilly drugs on their platform last month—both branded forms of tirzepatide—including Zepbound, a GLP-1 receptor agonist approved by the FDA for weight loss, and Mounjaro, which is not approved for weight loss but for the treatment of type 2 diabetes.4
As it stands, compounders are allowed to produce copies for people if the doses are not available in branded drugs, which is the situation in this particular case. However, the FDA has been looking into investigating if semaglutide and tirzepatide would be an exception to that, due to their complexity.
The company will be selling its compounded semaglutide for $149 for the first month; for context, Wegovy or Zepbound cost $349 for a 2.5-milligram vial.
This difference in price is due to a practice known as microdosing, which involves taking smaller doses of a drug as way to cut prices for the patient. In this case, patients would start with a 0.25-milligram dose and slowly increase their dosage to 2.4 milligrams—representing the FDA-approved maximum dose—over a span of 20 weeks.
The development comes during a time when GLP-1s continue to dominate conversations in the space, particularly when it comes to their capabilities for treating other indications. Doug Long, IQVIA’s vice president of industry relations, caught up with Pharma Commerce at the Asembia AXS25 Summit5 to discuss exactly that.
“Clinically, GLP-1s show potential beyond diabetes and obesity—there's promise in areas like sleep apnea and cardiovascular conditions,” he explained. “The bigger, long-term question is: if patients become significantly healthier through these medications, will they still need treatments for heart disease, high cholesterol, and related conditions? That shift, though, will likely take five or more years to materialize.
References
1. Niasse A. Weight-loss company Noom pivots to smaller doses of compounded Wegovy. Reuters. May 20, 2025. Accessed May 21, 2025. https://www.reuters.com/business/healthcare-pharmaceuticals/weight-loss-company-noom-pivots-smaller-doses-compounded-wegovy-2025-05-20/#xd_co_f=ZDlkZmUzYzktZWYwMS00ODJlLTliMWItNzVhOTAzYTlhN2Y5~
2. FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize. US Food & Drug Administration. April 28, 2025. Accessed May 21, 2025. https://www.fda.gov/drugs/drug-safety-and-availability/fda-clarifies-policies-compounders-national-glp-1-supply-begins-stabilize
3. Compounded semaglutide prescription online for weight loss. Noom. Accessed May 21, 2025. https://www.noom.com/med/compounded-semaglutide/
4. Saraceno N. Hims & Hers Begins Selling Zepbound. Pharmaceutical Commerce. April 2, 2025. Accessed May 21, 2025. https://www.pharmaceuticalcommerce.com/view/hims-hers-begins-selling-zepbound
5. Tracy D. Asembia 2025: GLP-1 Drugs Reshape Reimbursement and Coverage Models. Pharmaceutical Commerce. May 7, 2025. Accessed May 21, 2025. https://www.pharmaceuticalcommerce.com/view/asembia-2025-glp-1-drugs-reshape-reimbursement-coverage-models
